Welcome to our dedicated page for Abcellera Biologics news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on Abcellera Biologics stock.
AbCellera Biologics (NASDAQ: ABCL) operates at the intersection of biotechnology and drug discovery, making its news feed particularly relevant for investors tracking the antibody therapeutics space. As a platform company that partners with pharmaceutical giants to discover monoclonal antibodies, AbCellera's announcements often signal broader trends in the therapeutics pipeline landscape.
News coverage for ABCL typically centers on partnership announcements and program milestones. When AbCellera discloses new collaborations or reports that partner programs have advanced to new clinical phases, these developments directly impact the company's future milestone and royalty revenue streams. Each clinical trial progression represents both validation of the discovery platform and potential future income.
Quarterly earnings releases reveal how AbCellera's partnership economics translate into financial performance. Beyond headline numbers, these reports detail the status of partner programs, new agreements signed, and updates on the company's proprietary internal pipeline. For a platform-based biotech, understanding the partnership pipeline is essential context.
Clinical trial updates feature prominently in AbCellera's news flow. The company's internal programs generate announcements around trial initiations, interim data readouts, and regulatory interactions. Additionally, positive developments from partner programs—where AbCellera discovered the underlying antibody—often merit disclosure given milestone payment implications.
Patent and intellectual property news matters for platform companies. AbCellera's microfluidic technology represents a core competitive advantage, and developments related to patent protection or technology licensing can affect the company's market position.
Bookmark this page to follow AbCellera's developments as the company advances its antibody discovery platform and expands its therapeutic pipeline.
AbCellera (Nasdaq: ABCL) announced a positive scientific opinion from the EMA's CHMP for the use of bamlanivimab alone and in combination with etesevimab for treating COVID-19 in high-risk patients aged 12 and older. This recommendation allows EU member states to make informed decisions on therapy usage before market authorization. The CHMP opinion was backed by positive results from Eli Lilly's BLAZE-1 trial, showing a 70% reduction in hospitalization rates. Bamlanivimab has also received authorization in over 10 countries and generated $871 million in sales in 2020.
AbCellera (NASDAQ: ABCL) will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 1:20 p.m. PT. A live audio webcast will be accessible on AbCellera’s Investor Relations website, with a replay available afterward. AbCellera is a technology company focused on discovering antibodies from natural immune systems, partnering with drug developers to accelerate drug development and reduce costs. The press release includes forward-looking statements about potential risks and uncertainties in their business operations.
AbCellera (Nasdaq: ABCL) has appointed Ester Falconer, Ph.D., as Chief Technology Officer effective January 28, 2021. Dr. Falconer will oversee the company's strategy to enhance therapeutic antibody discovery technologies. Previously, she led R&D at AbCellera and contributed significantly to the development of the COVID-19 therapeutic bamlanivimab. Her appointment is expected to strengthen leadership and innovation within the company. Dr. Falconer has been with AbCellera since 2015, advancing through various roles, and holds a Ph.D. in genetics and cell biology.
AbCellera (Nasdaq: ABCL) announced that bamlanivimab (LY-CoV555) 700 mg, developed with Eli Lilly, received Emergency Use Authorization (EUA) from the FDA for treating mild to moderate COVID-19 in high-risk patients. The therapy demonstrated a 70% reduction in hospitalizations in the Phase 3 BLAZE-1 trial, which involved over 1,000 patients. Lilly plans to manufacture over 250,000 doses in Q1 2021. Bamlanivimab, developed from an antibody discovered in a recovered COVID-19 patient, is part of AbCellera's pandemic response efforts, identifying over 2,300 unique antibodies.
AbCellera (Nasdaq: ABCL) is set to announce its fourth-quarter and full-year 2020 financial results on March 29, 2021, after U.S. market close. An earnings conference call will follow at 2:00 p.m. PT (5:00 p.m. ET). The live webcast will be accessible via AbCellera’s Investor Relations website, with a replay available post-call.
AbCellera specializes in discovering and analyzing antibodies for drug development, collaborating with various drug developers to streamline processes and reduce costs.
AbCellera (Nasdaq: ABCL) announced that its antibody, bamlanivimab, will be evaluated alongside VIR-7831 as a potential COVID-19 therapy for low-risk patients with mild to moderate illness. Bamlanivimab has been shown to reduce the risk of COVID-19 by up to 80%, prevent deaths, and decrease hospitalizations by 70%-80%. Currently authorized in multiple countries, bamlanivimab was developed in partnership with Eli Lilly and has been administered to over 100,000 patients since receiving Emergency Use Authorization from the FDA in November 2020.
AbCellera (Nasdaq: ABCL) has announced compelling results from the BLAZE-1 Phase 2/3 study, where bamlanivimab and etesevimab significantly reduced COVID-19-related hospitalizations and deaths by 70% compared to placebo. In a trial involving over 1,000 high-risk patients, all deaths occurred in the placebo group. Bamlanivimab was the first monoclonal antibody authorized by the FDA for COVID-19 treatment. AbCellera continues to enhance its pandemic response capabilities, having identified over 2,300 unique anti-SARS-CoV-2 antibodies.
AbCellera (Nasdaq: ABCL) announced that its antibody, bamlanivimab (LY-CoV555), demonstrated a significant reduction in COVID-19 risk among long-term care residents and staff in the Phase 3 BLAZE-2 trial. Data showed an up to 80% risk reduction in COVID-19 contraction for residents receiving bamlanivimab compared to placebo. Importantly, no COVID-19 related deaths were reported in the bamlanivimab group. The trial, in partnership with Lilly and NIAID, highlights the potential of bamlanivimab in preventing COVID-19, especially among vulnerable populations.
AbCellera (Nasdaq: ABCL) has expanded its intellectual property portfolio with the issuance of patent no. 10,881,084 for its Trianni Mouse® technology, aimed at enhancing antibody discovery. This technology allows the generation of fully human monoclonal antibodies, significantly increasing the speed and efficiency of therapeutic antibody development with partners. Carl Hansen, CEO, emphasized the patent's importance for protecting their proprietary technology in the U.S. The Trianni Mouse® platform is a key asset for developing advanced transgenic mouse technologies.
AbCellera (Nasdaq: ABCL) announced that bamlanivimab (LY-CoV555), developed with Eli Lilly, will undergo a new pragmatic study targeting high-risk COVID-19 patients. This collaboration, with support from New Mexico, aims to evaluate bamlanivimab's effectiveness and safety in diverse environments. The antibody, authorized in the U.S. and Canada, has demonstrated success in reducing viral load and hospitalizations in previous studies. This initiative aligns with AbCellera's efforts in pandemic response, showcasing its capabilities developed over two years under DARPA's program.
FAQ
What is the current stock price of Abcellera Biologics (ABCL)?
What is the market cap of Abcellera Biologics (ABCL)?
